Trial
NCT00520533
Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma
Phase ITERMINATEDSAFETYConfidence: HIGH
Sponsor
Ludwig Institute for Cancer Research
Collaborators
Pfizer; Heidelberg Pharma AG
Condition
Renal Cell Carcinoma (RCC)
Intervention
Chimeric monoclonal antibody cG250
Why stopped
Closed prematurely due to toxicity
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-10-12